132257-11-5 Usage
Uses
Used in Pharmaceutical Industry:
N-[2-[3-Methoxy-4-(phenylMethoxy)phenyl]ethyl]-4-(phenylMethoxy)benzeneacetaMide is used as an intermediate in the synthesis of Coclaurine (C633550) for its potential therapeutic applications. Coclaurine, a benzyltetrahydroisoquinoline alkaloid, has been extracted from Magnolia salicifolia and is being studied for its potential medicinal properties, such as its ability to act as an anti-inflammatory, analgesic, and antipyretic agent.
Additionally, Coclaurine may have potential applications in the treatment of neurological disorders, as it has been found to exhibit neuroprotective effects and modulate various signaling pathways involved in neurodegenerative diseases. The synthesis of Coclaurine relies on the use of N-[2-[3-Methoxy-4-(phenylMethoxy)phenyl]ethyl]-4-(phenylMethoxy)benzeneacetaMide as a key intermediate, highlighting its importance in the development of new pharmaceutical agents.
Check Digit Verification of cas no
The CAS Registry Mumber 132257-11-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,2,2,5 and 7 respectively; the second part has 2 digits, 1 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 132257-11:
(8*1)+(7*3)+(6*2)+(5*2)+(4*5)+(3*7)+(2*1)+(1*1)=95
95 % 10 = 5
So 132257-11-5 is a valid CAS Registry Number.
132257-11-5Relevant articles and documents
Designing new analogs for streamlining the structure of cytotoxic lamellarin natural products
Tangdenpaisal, Kassrin,Worayuthakarn, Rattana,Karnkla, Supatra,Ploypradith, Poonsakdi,Intachote, Pakamas,Sengsai, Suchada,Saimanee, Busakorn,Ruchirawat, Somsak,Chittchang, Montakarn
, p. 925 - 937 (2015/03/31)
Despite the therapeutic potential of marine-derived lamellarin natural products, their preclinical development has been hampered by their lipophilic nature, causing very poor aqueous solubility. In order to develop more drug-like analogs, their structure was streamlined in this study from both the cytotoxic activity and lipophilicity standpoints. First, a modified total synthetic route was successfully devised to construct a library of 59 systematically designed lamellarin analogs, which were then subjected to cytotoxicity and log P determinations. Along with the 25 first-generation lamellarins previously synthesized in our laboratory, the structure-activity and structure-lipophilicity relationships were extensively evaluated. Our results clearly indicated the additional structural requirements around the lamellarin skeleton which, when combined with those reported previously, can provide invaluable guidance for further modifications to increase the aqueous solubility of these compounds.
